Microbot Medical Inc. has announced it has secured a U.S.-based third-party logistics partner to support the commercialization of its FDA-cleared LIBERTY Endovascular Robotic System. The logistics provider specializes in the medical device industry and will assist with inventory management, order processing, and customer support from a climate-controlled warehouse. Microbot Medical is expected to begin a limited market release of the LIBERTY System in the fourth quarter of 2025, with a broader launch planned for April 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microbot Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544918-en) on October 14, 2025, and is solely responsible for the information contained therein.
Comments